Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8386 to 8400 of 8963 results

  1. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued

  2. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  3. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

    Technology appraisal guidance
    Discontinued

  4. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued Reference number: GID-TAG399

    Technology appraisal guidance
    Discontinued

  5. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued Reference number: GID-TAG372

    Technology appraisal guidance
    Discontinued

  6. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued

  7. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

    Technology appraisal guidance
    Discontinued

  8. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

    Technology appraisal guidance
    Discontinued

  9. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

    NICE guideline
    Discontinued

  10. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  11. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued Reference number: GID-TA10447

    Technology appraisal guidance
    Discontinued

  12. Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]

    Discontinued Reference number: GID-TA10686

    Technology appraisal guidance
    Discontinued

  13. Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

    Discontinued Reference number: GID-TA10397

    Technology appraisal guidance
    Discontinued

  14. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued Reference number: GID-TA10631

    Technology appraisal guidance
    Discontinued

  15. Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

    Discontinued Reference number: GID-TA10609

    Technology appraisal guidance
    Discontinued